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Summary
Objectives: Serum ferritin is one of the markers indicating hemophagocytosis that may have a
role in the pathogenesis of Crimean-Congo hemorrhagic fever (CCHF). This study was designed to
determine any correlation between serum ferritin and routine diagnostic laboratory markers of
CCHF, and to investigate the relationship between serum ferritin levels and disease severity.
Methods: Sixty-six patients with CCHF admitted to the hospital during the spring and summer
months of 2006 and 2007 were included in the study. Serum ferritin levels were measured in sera
obtained during the initial days of hospitalization. Data from 53 patients showing decreasing
platelet counts over the first three days were used for further analysis and these patients were
divided into two groups according to disease severity: group A included severe cases with lowest
platelet counts 20  109/l and group B included mild cases with lowest platelet counts
>20  109/l.
Results: Forty patients (60.6%) were male (mean age 43  17 years). Three patients died, thus
the fatality rate was 4.5%. Fifty-one patients (77.3%) had abnormal serum ferritin levels, with
levels above 500 ng/ml in 62.1%. There was a significant negative correlation between ferritin
levels and concordant platelet counts ( p < 0.001; r = 0.416) and ferritin was also found to be
positively correlated with aspartate aminotransferase ( p < 0.001; r = 0.625), alanine amino-
transferase (p < 0.001; r = 0.479), and lactate dehydrogenase (p < 0.001; r = 0.684). Group A
had higher ferritin levels than group B (p < 0.001). Receiver operating characteristic analysis
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revealed that a ferritin level of1862 ng/ml had a sensitivity of 87.5% and a specificity of 83.8% in
differentiating severe cases from mild ones.
Conclusions: Increased serum ferritin levels may suggest a significant role of hemophagocytosis in
the pathogenesis of CCHF andmay be a useful marker for diagnosis, disease activity, and prognosis.
# 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Crimean-Congo hemorrhagic fever (CCHF) is a potentially
fatal viral disease caused by a Nairovirus belonging the family
Bunyaviridae. It has been described in parts of Africa, Asia,
Eastern Europe, and the Middle East and has a case—fatality
of 3—80%. Humans are infected by Hyalomma ticks or by
handling the blood or secretions of infected people or domes-
tic animals. CCHF has been reported to be endemic in some
regions of Turkey, especially in the Middle Black Sea Region
during the summer months over the last five years, and is one
of the important public health issues in Turkey because of its
high fatality rate.1—4
Ferritin is a positive acute phase protein whose levels
increase in the presence of various acute or chronic disease
conditions. Extremely elevated serum ferritin levels have
been found in histiocytic malignancies and adult-onset Still’s
disease as well as hemophagocytic lymphohistiocytosis
(HLH).5—7 HLH is a rare and serious clinical form of CCHF,2,8
and is characterized by fever, hepatosplenomegaly, cytope-
nia, elevated triglyceride, lactate dehydrogenase (LDH) and
ferritin levels, and hemophagocytosis in bone marrow, liver
and lymph nodes, associated with excessive production of
various cytokines by hyper-activated T helper lymphocytes
and macrophages.9—11 Serum ferritin is an important diag-
nostic laboratory marker of HLH, and is frequently higher
than 500 ng/ml in patients with HLH.7,12 To date, there has
been only one study2 that has reported the elevation of serum
ferritin levels in CCHF.
In the present study, serum ferritin levels, a diagnostic
marker of HLH, were investigated in CCHF patients. We
aimed to determine whether serum ferritin levels were more
increased in severe cases than in milder cases, and to deter-
mine any correlation between ferritin and other important
laboratory markers in clinical practice, such as platelet count
or biochemical enzyme levels.
Methods
We retrospectively evaluated patients with acute febrile
syndrome, characterized by malaise, bleeding, leukopenia,
and thrombocytopenia, who were admitted to the infectious
diseases clinics of Tokat Cevdet Aykan State Hospital or
Gaziosmanpasa University School of Medicine Training Hos-
pital during the spring and summer of 2006 and 2007, and
diagnosed with CCHF. Because CCHF is endemic in Tokat
Province, all patients with symptoms or signs compatible
with CCHF were considered probable cases. Three probable
cases and 63 cases that were confirmed by positive serology
or by detection of CCHF virus nucleic acid were included in
the study. None of the patients received specific or suppor-
tive treatment other than intravenous fluids and/or anti-
pyretics.Patient serum samples obtained within three days of
admission to the hospital represented the acute phase sam-
ple. Part of each sample was kept at 40 8C for further
analysis, while the rest was immediately sent to the Refik
Saydam Hygiene Center in Ankara for ELISA and PCR test-
ing.13,14 Patients who had positive IgM and/or positive PCR
results for CCHF virus were included in the study. Complete
blood counts of patients were measured on a daily basis
following admission to the hospital, and biochemical para-
meters (aspartate aminotransferase (AST), alanine amino-
transferase (ALT), creatine phosphokinase (CK), and LDH)
were tested within 48 hours of hospitalization.
Ferritin was measured using a commercial electrochemi-
luminescence kit (Roche Diagnostics GmbH, Mannheim, Ger-
many) according to themanufacturer’s guidelines. The serum
AST/ALTratio was calculated for all patients. We investigated
whether ferritin level was related to other concordant
laboratory parameters (platelet count, AST, ALT, CK, LDH,
and AST/ALT ratio).
To make a more homogeneous group, cases admitted to
the hospital late were excluded and the remaining 53
patients showing a decreasing platelet count over the first
three days of hospitalization were included in further ana-
lysis. These patients were divided into two groups according
to disease severity. Swanepoel et al. have described the
fatality criteria in CCHF.15 According to these criteria,
patients are defined as having severe disease if they have
a leukocyte count 10 109/l, a platelet count 20 109/l,
an AST level >200 U/l, an ALT level >150 U/l, an activated
partial thromboplastin time (aPTT) >60 seconds, and/or a
fibrinogen level <110 mg/dl during the first five days after
onset of illness. None of our patients showed an increase in
aPTT in the first three days and fibrinogen was not examined.
The levels of AST and ALT that predict fatality are contro-
versial. In a recent report by Cevik et al.,16 a platelet count
20 109/l has been found to be independently associated
with mortality, whereas AST or ALT have not been indepen-
dent predictors of fatality. Thus we used the criterion of a
platelet count 20109/l to differentiate severe cases from
mild cases. Patients whose platelet counts decreased to 20
109/l any time during hospitalization were considered as
severe cases. After excluding late admission cases, the
patients with lowest platelet counts 20 109/l were
assigned to group A, while those with lowest platelet counts
>20 109/l to group B. Serum ferritin levels, AST, ALT, CK,
LDH activities, and AST/ALT ratios in acute phase sera of the
patients (within the first three days of hospitalization, mostly
pre-hemorrhagic) were compared between these two groups.
Statistical analysis
The Mann—Whitney U-test was used to compare the contin-
uous parameters between group A and group B. Spearman
correlation analysis was performed for correlation between
Table 1 Demographic and laboratory parameters of
patients who died
Parameter Patient 1 Patient 2 Patient 3
Age (years) 64 69 45
Gender (M/F) M M F
Lowest platelet
count (109/l)
2.000 17.000 3.000
Ferritin (ng/ml) 12 126 8694 6426
AST/ALT ratio 3.45 2.02 3.46
AST (U/ml) 207 168 267
ALT (U/ml) 60 83 77
CK (U/ml) 1387 108 636
M, male; F, female; AST, aspartate aminotransferase; ALT, alanine
aminotransferase; CK, creatine phosphokinase.
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operating characteristics (ROC) curve was used to determine
the performance of ferritin level as a severity criterion
according to platelet count. All variables are presented as
mean  standard deviation (SD) and range. A p-value of
<0.05 was considered significant. Analyses were performed
using commercial software SPSS 16.0 (demo version; SPSS,
Inc., Chicago, IL, USA).
Results
Sixty-six subjects with CCHF were included in the study. Forty
patients (60.6%) were male. The mean age was 43  18
(range 12—83) years. Three patients in the study group,
whowere referred to another treatment center due to severe
thrombocytopenia and hemorrhagic complications, died;
thus the fatality rate was 4.5%. The lowest serum ferritin
level of fatal cases was 6426 ng/ml. Demographic and labora-
tory parameters of fatal cases are summarized in Table 1.
Serum ferritin levels of all patients varied between 59 and
34 660 with a mean value of 5370 ng/ml. Fifty-one patients
(77.3%) had abnormal serum ferritin levels. In forty-one
patients (62.1%), serum ferritin levels were above 500 ng/
ml. A significant negative correlation was observed between
ferritin level and platelet count, which were the mean values
of the first three days of hospitalization ( p < 0.001;Table 2 Demographic characteristics and laboratory findings of p
correlation analysis between ferritin and other laboratory parame
n Mean  SD
Ferritin (ng/ml) 66 5370  8088
Age (years) 66 43.36  17.87
Platelet count ( 109/l) 66 98.659  43.821
AST (U/ml) 64 120.45  86.67
ALT (U/ml) 64 59.55  52.61
AST/ALT ratio 64 2.16  0.78
CK (U/ml) 46 426.09  540.13
LDH (U/ml) 27 370.81  184.88
SD, standard deviation; AST, aspartate aminotransferase; ALT, alani
dehydrogenase.
a Spearman correlation coefficients between ferritin and other paramr = 0.416). Ferritin was found to be positively correlated
with AST ( p < 0.001; r = 0.625), ALT ( p < 0.001; r = 0.479),
and LDH ( p < 0.001; r = 0.684) (Table 2).
Thirteen cases were excluded due to late admission and
the remaining 53 cases were divided into two groups: group A
(severe) included 16 cases and group B (mild) included 37
cases. There was no difference between the groups regarding
time to reach the lowest platelet count (the mean time was
4.13 days for group A and 4.097 days for group B). However,
serum ferritin levels were significantly higher in severe cases
(group A) compared to mild cases (group B) ( p < 0.001;
Table 3). The serum AST/ALT ratio was an important prog-
nostic factor in our patient population. We found a signifi-
cantly higher AST/ALT ratio in group A compared to group B
( p < 0.001) (Table 3).
To determine ferritin threshold as a severity criterion, a
ROC analysis was carried out. The area under the curve was
0.875 ( p < 0.001) and a ferritin level of 1862 ng/ml was
found to have a sensitivity of 87.5% and a specificity of 83.8%
in differentiating severe cases from mild ones (Figure 1).
Discussion
In this study, we retrospectively analyzed 66 cases diagnosed
with CCHF. CCHF was first recognized in Turkey in 2002. Most
of the cases have been reported in the Middle Black Sea and
Northern Central Anatolia regions, indicating that CCHF is
endemic to those regions of Turkey.2,3,8,17 Tokat Province, in
which our patients reside, is located within the endemic
region and is in fact the province where the first human
CCHF cases appeared in Turkey. During the last five years, an
increasing number of human CCHF virus infections has been
reported from various parts of Turkey.18
Although the pathogenesis of CCHF infection is still not
clear, hemophagocytosis, a symptom rarely reported in viral
hemorrhagic fevers, was initially observed in patients with
CCHF by Karti et al.8 Recently, two new reports of hemo-
phagocytic syndrome associated with CCHF in Turkey have
been published.2,19 HLH is an uncommon syndrome charac-
terized by a reactive, systemic proliferation of benign his-
tiocytes throughout the reticuloendothelial system. HLH
comprises two different conditions that may be difficult to
distinguish from one another: a primary and a secondaryatients with Crimean-Congo hemorrhagic fever and results of
ters (N = 66)
Range ra p-Value
59—34 660
12—83 0.170 0.172
26.000—239.670 0.416 <0.001
19—350 0.625 <0.001
12—309 0.479 <0.001
1.05—4.31 0.495 <0.001
38—2726 0.201 0.179
175—752 0.684 <0.001
ne aminotransferase; CK, creatine phosphokinase; LDH, lactate
eters.
Table 3 Comparison of laboratory results between severe (group A) and mild (group B) cases according to the criterion
thrombocytopenia of 20 109/l (n = 53)
Parameter Group A Group B p-Value
Mean  SD Range Mean  SD Range
Days to lowest
platelet count
4.133 2—7 4.097 2—7 0.990
Ferritin (ng/ml) 12194.81  9618 105—34660 2003.55  3955 59—13250 <0.001b
Platelet count
(at baseline)
(109/l)
87.479  46.705 48.000—217.330 109.446  38.885 39.000—239.670 0.021a
AST (U/ml) 134.88  54.12 32—267 92.72  86.04 19—332 0.005a
ALT (U/ml) 49  14.38 27—77 53.42  59.67 12—309 0.57
CK (U/ml) 698.21  778.88 53—2726 364.50  382.77 73—1236 0.263
LDH (U/ml) 457.5  216.71 245—752 280.5  117.68 175—638 0.026a
AST/ALT ratio 2.75  0.85 1.19—4.06 1.87  0.46 1.07—2.90 <0.001b
SD, standard deviation; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CK, creatine phosphokinase; LDH, lactate
dehydrogenase.
a Statistically significant.
b Highly statistically significant.
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phagocytic lymphohistiocytosis (FHL), is a fatal disease with a
median survival expressed in months after diagnosis if left
untreated, and typically has its onset during infancy or early
childhood. Importantly, the onset of FHL and bouts of the
disease may be triggered by infections. Secondary HLH
(SHLH) may develop as a result of strong immunological
activation of the immune system, which may, for example,
be caused by a severe infection, particularly systemic viral
infections (Epstein—Barr virus, cytomegalovirus, CCHF) and
occasionally with bacterial, fungal, or parasitic infections.
For most patients with HLH, the outcome is rapid and fatalFigure 1 Receiver operating characteristics curve showing the
performance of serum ferritin as a predictor of severity (area
under curve = 0.875; p < 0.001).unless the diagnosis is made early and followed by prompt
therapeutic intervention.9,12,20,21 Recent studies indicate
that HLH is seen in nearly half of the patients with CCHF
in Turkey. HLH is the most important clinical phenomenon
associated with the outcome of the infection.2,8
The most typical findings of HLH are fever, hepatospleno-
megaly, and cytopenia (most commonly thrombocytopenia
and anemia). Cytopenia affects at least two of three lineages
in the peripheral blood. Other common findings include hyper-
triglyceridemia, coagulopathy with hypofibrinogenemia, liver
dysfunction, elevated levels of ferritin (>500 ng/ml) and
serum transaminases, and neurological symptoms. Sponta-
neous partial remissions are observed.11,12,20,21 Cytopenia
and hyperferritinemia in patients with CCHF may result from
HLH.2,8,19 Cytopenia during HLH has been attributed primarily
to high concentrations of tumor necrosis factor alpha (TNF-a)
and interferon-g.11 In the present study, we observed evident
thrombocytopenia in 30.3% and increased ferritin levels in
77.3% of all patients.
Ferritin, the major iron storage protein, plays a key role in
iron metabolism. Serum ferritin concentration provides an
indirect estimate of body iron stores, because it is highly
correlated with bone marrow iron. Ferritin is also a positive
acute-phase reactant and increases in the presence of var-
ious acute or chronic disease conditions. Elevated serum
ferritin levels have also been found in liver necrosis, chronic
inflammation-related diseases, histiocytic malignancies, and
adult-onset Still’s disease as well as HLH.6,22 Serum ferritin
levels are above 500 ng/ml in CCHF patients with HLH.2
Patients with infection-associated HLH usually have persis-
tent unexplained fever, cytopenia, lymphadenopathy, and
frequently hepatosplenomegaly and coagulopathy. The pos-
sible immunopathologic mechanism of HLH might be exces-
sive production of Th1 cytokines such as interferon-g, TNF-a,
interleukin (IL)-1, or IL-6 from activated lymphocytes or
monocytes.9 Two studies have reported elevations in proin-
flammatory cytokines in CCHF. Ergonul et al.23 found that the
levels of IL-1, IL-6, and TNF-a were higher among patients
who subsequently died compared with those who survived.
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most often detected during a CCHF viral infection, and that
TNF-awas associated with the severe form of CCHF while IL-6
was elevated in both severe and mild cases. Leukopenia,
thrombocytopenia, coagulopathy, and hyperferritinemia in
patients with CCHF may be caused by hypercytokinemia, as is
the case in HLH.
In the current study, we found ferritin levels above 500 ng/
ml in 62.1% of all patients with CCHF and in 95% (19/20) of
patients with severe case definition. This finding, as well as
the negative correlation of ferritin with the platelet count,
the positive correlation of ferritin with AST, ALT, and LDH, and
the presence of higher levels of ferritin in severe cases, all
indicate that ferritin can be used as a severity marker,
beyond a diagnostic tool for CCHF. Moreover, we established
that a 1862 ng/ml threshold level for ferritin has the most
reliable sensitivity and specificity in determining the severe
cases. In this study, we used only the thrombocytopenia of
20 109/l criterion to identify severe cases because the
number of fatal cases was not sufficient to compare fatal and
nonfatal cases; this may be a limitation of our study. Addi-
tionally we could not examine ferritin in the days subsequent
to hospitalization.
Ergonul et al.25 suggested that a high AST/ALT ratio was a
prognostic factor for severity among cases of CCHF, and the
same parameter was documented to be a prognostic factor
for fatality. Our results are concordant with the literature.
Hemophagocytosis is suggested to have a role in the
development of cytopenia in CCHF, the mechanism of which
still needs to be investigated, probably with cytokine studies.
Together with clinical symptoms and patient history, hemo-
phagocytosis may be an indicator of CCHF. In conclusion, our
study confirms other reports that have shown elevated serum
ferritin levels in patients with CCHF. In addition, serum
ferritin levels in CCHF may be a useful marker of disease
activity and prognosis. New studies are needed to clarify on
which day ferritin levels begin to increase after the onset of
symptoms and factors that lead to increases in ferritin levels.
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